

FORM PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN.003C1

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
PL	1	4,757,006	Jul. 12, 1988	Toole, Jr. <i>et al.</i>			Oct. 28, 1983
	2	4,886,876	Dec. 12, 1989	Zimmerman <i>et al.</i>			Apr. 13, 1987
	3	5,004,803	Apr. 2, 1991	Kaufman <i>et al.</i>			Nov. 14, 1988
	4	5,045,455	Sept. 3, 1991	Kuo <i>et al.</i>			June 14, 1990
	5	5,112,950	May 12, 1992	Meulien <i>et al.</i>			June 26, 1991
	6	5,139,941	Aug. 18, 1992	Muzyczka <i>et al.</i>			Oct. 25, 1991
	7	5,149,637	Sept. 22, 1992	Scandella <i>et al.</i>			Sept. 20, 1990
	8	5,171,844	Dec. 15, 1992	van Ooyen <i>et al.</i>			June 10, 1988
	9	5,173,414	Dec. 22, 1992	Lebkowski <i>et al.</i>			Oct. 30, 1990
	10	5,422,260	June 6, 1995	Kaufman <i>et al.</i>			May 15, 1992
	11	5,451,521	Sept. 19, 1995	Kaufman <i>et al.</i>			Dec. 9, 1986
	12	5,595,886	Jan. 21, 1997	Chapman <i>et al.</i>			Dec. 3, 1993
	13	5,563,045	Oct. 8, 1996	Pittman <i>et al.</i>			Sept. 14, 1993
	14	5,587,310	Dec. 24, 1996	Kane <i>et al.</i>			July 11, 1994
	15	5,622,856	Apr. 22, 1997	Natsoulis			Aug. 3, 1995
	16	5,633,150	May 27, 1997	Wood <i>et al.</i>			Oct. 9, 1990
	17	5,661,008	Aut. 26, 1997	Almstedt <i>et al.</i>			Jun. 5, 1995
	18	5,668,108	Sept. 16, 1997	Capon <i>et al.</i>			May 23, 1995
	19	5,681,746	Oct. 28, 1997	Bodner <i>et al.</i>			Dec. 30, 1994
	20	5,693,499	Dec. 2, 1997	Yonemura <i>et al.</i>			Jul. 18, 1994
	21	5,720,720	Feb. 24, 1998	Laske <i>et al.</i>			Mar. 15, 1996
	22	5,789,203	Aug. 4, 1998	Chapman <i>et al.</i>			Jun. 27, 1994
	23	5,858,351	Jan. 12, 1999	Podsakoff <i>et al.</i>			Jan. 18, 1996
DL	24	5,846,528	Dec. 8, 1998	Podsakoff <i>et al.</i>			Jan. 16, 1997

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
PL	25	WO 87/07144	Dec. 3, 1987	PCT WIPO				
	26	WO 91/07490	May 30, 1991	PCT				
	27	WO 91/09122	June 27, 1991	PCT				
	28	WO 92/01070	Jan. 23, 1992	PCT				
	29	WO 92/08981	May 29, 1992	PCT				
	30	WO 92/16557	Oct. 1, 1992	PCT				
DL	31	WO 93/03367	Feb. 18, 1993	PCT WIPO				

Examiner: *Brian A. Altman*

Date Considered: 11/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN, 003C1

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

DW	32	WO 93/03769	Mar. 4, 1993	PCT WIFO				
	33	WO 94/11503	May 26, 1994	PCT				
	34	WO 96/21035	July 11, 1996	PCT				
	35	WO 97/03195	Jan. 30, 1997	PCT WIFO				
	36	EP 0 160 457	Jan. 16, 1991	EP				
	37	EP 0 162 067	July 15, 1992	EP				
	38	EP 0 182 448	May 28, 1986	EP				
	39	EP 0 220 618	Oct. 16, 1986	EP				
	40	EP 0 232 112	Dec. 1, 1993	EP				
	41	EP 0 500 734	Feb. 11, 1998	EP				
	42	EP 0 506 757	Aug. 26, 1998	EP				
	43	EP 0 533 862	Oct. 27, 1999	EP				
	44	EP 0 670 332	Sept. 6, 1995	EP				
	45	EP 0 672 138	Sept. 20, 1995	EP				
	46	EP 0 786 474	July 30, 1997	EP				
	47	EP 0 795 021	Sept. 17, 1997	EP				
DW	48	EP 0 874 057	Oct. 28, 1998	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

DW	49	Aiello <i>et al.</i> , "Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293) <i>Virol.</i> , 94:460-469 (1979);
	50	Antonarakis <i>et al.</i> , "Molecular Genetics of Hemophilia A in Man (Factor VIII Deficiency)," <i>Mol. Biol. Med.</i> , 4:81-94 (1987)
	51	Berns, "Parvoviridae and Their Replication," in Fields and Knipes (eds.), <i>Fundamental Virology</i> , 2nd Edition, pp. 817-837 (1991);
	52	Boshart <i>et al.</i> , "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <i>Cell</i> 41:521-530 (1985);
	53	Buller <i>et al.</i> , "Herpes Simplex Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication," <i>J. Virol.</i> , 40:241-247 (1981)
	54	Capecchi, "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <i>Cell</i> 22:479-488 (1980);
	55	Carter, "Adeno-Associated Virus Helper Functions," in <i>CRC Handbook of Parvoviruses</i> , Vol. I (P. Tijssen, ed.), pp. 533-539 (1990);
	56	Carter, "Adeno-associated virus vectors," <i>Curr. Opin. Biol.</i> , 3:533-539 (1992);
	57	Chu <i>et al.</i> , "SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen," <i>Gene</i> 13:197-202 (1981);
	58	Costa and Grayson, "Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region," <i>Nucl. Acids. Res.</i> , 19:4139-4145 (1991)
	59	Costa <i>et al.</i> , "Transcriptional Control of the Mouse Prealbumin (Transthyretin) Gene: Both Promoter Sequences and a Distinct Enhancer Are Cell Specific," <i>Mol. Cell. Biol.</i> , 6:4697 (1986)
	60	Davis <i>et al.</i> , <i>Basic Methods in Molecular Biology</i> , Elsevier (1986) (Title and Copyright Pages Only);
	61	Dijkema <i>et al.</i> , "Cloning and expression of the chromosomal immune interferon gene of the rat," <i>EMBO J.</i> 4:761-767 (1985);
DW	62	Edge, "Total Synthesis Of A Human Leukocyte Interferon Gene", <i>Nature</i> 292:756-761(1981);

Examiner: Baird H. Hines

Date Considered: 9/1/84 11/9/82

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN, 06321

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

63	Felgner <i>et al.</i> , "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84: 7413-7417 (1987);
64	Ganz <i>et al.</i> , "Human factor VIII from heparinized plasma: purification and characterization of a single-chain form," <i>Eur. J. Biochem.</i> , 170:521-528 (1988);
65	Glover <i>et al.</i> (ed.), <i>DNA Cloning: A Practical Approach</i> , vols. I and II, Oxford; New York: IRL Press (1995) (Title and Copyright Pages Only)
66	Gorman <i>et al.</i> , "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc. Natl. Acad. Sci. USA</i> 79: 6777-6781 (1982);
67	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," <i>Virol.</i> , 52: 456-467 (1973);
68	Graham <i>et al.</i> , "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," <i>J. Gen. Virol.</i> , 36:59-72 (1977);
69	Herzog <i>et al.</i> , "Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector," <i>Nature Med.</i> , 5:56-63 (1999);
70	Janik <i>et al.</i> , "Locations of adenovirus genes required for the replication of adenovirus-associated virus," <i>Proc. Natl. Acad. Sci. USA</i> 78:1925-1929 (1981);
71	Jay <i>et al.</i> , "Chemical Synthesis Of A Biologically Active Gene For Human Immune Interferon- γ ," <i>J. Biol. Chem.</i> 259:6311-6317 (1984);
72	Kaufman <i>et al.</i> , "Synthesis, Processing, and Secretion of Recombinant Human Factor VII Expressed in Mammalian Cells," <i>J. Biol. Chem.</i> , 263:6352-6362 (1988);
73	Kaufman, "Biological Regulation of Factor VIII Activity," <i>Ann. Rev. Med.</i> , 43:325-339 (1992);
74	Kim <i>et al.</i> , "Use of the human elongation factor 1 α promoter as a versatile and efficient expression system," <i>Gene</i> 91:217-223 (1990);
75	Klein <i>et al.</i> , "High-velocity microprojectives for delivering nucleic acids into living cells," <i>Nature</i> 327:70-73 (1987);
76	Kotin, "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," <i>Hum. Gen. Ther.</i> , 5:793-801 (1994);
77	Lebkowski <i>et al.</i> , "Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types," <i>Mol. Cell. Biol.</i> , 8:3988-3996 (1988);
78	Lind <i>et al.</i> , "Novel forms of B-domain-deleted recombinant factor VIII molecules: construction and biochemical characterization," <i>Eur. J. Biochem.</i> , 232:19-27 (1995);
79	Maniatis <i>et al.</i> , "Regulation of Inducible and Tissue-Specific Gene Expression," <i>Science</i> 236: 1237-1244 (1987);
80	Mannino <i>et al.</i> , "Liposome Mediated Gene Transfer," <i>BioTechn.</i> , 6:682-690 (1988);
81	Matsushita <i>et al.</i> , "Adeno-associated virus vectors can be efficiently produced without helper virus," <i>Gene Ther.</i> , 5:938-945 (1998);
82	McCarty <i>et al.</i> , "Sequences Required for Coordinate Induction of Adeno-Associated Virus p19 and p40 Promoters by Rep Protein," <i>J. Virol.</i> , 65:2936-2945 (1991);
83	McPherson <i>et al.</i> , "Human Cytomegalovirus Completely Helps Adeno-Associated Virus Replication," <i>Virol.</i> , 147:217-222 (1985);
84	Mizushima and Nagata, "pEF-BOS, a powerful mammalian expression vector," <i>Nucl. Acids. Res.</i> , 18:5322 (1990);
85	Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," <i>Curr. Top. Microbiol. Immunol.</i> , 158:97-129 (1992);
86	Nakai <i>et al.</i> , <i>Blood</i> 91:1-9 (1998); Reference could not be obtained at this time. Will provide a copy at a later date should the Examiner desire a copy.
87	Nambair <i>et al.</i> , "Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," <i>Science</i> 223:1299-1301 [1984];
88	<i>Remington's Pharmaceutical Sciences</i> 18th ed., Easton, Pa: Mack Pub. Co. [1990]; Reference could not be obtained at this time. Will provide a copy of the Title and Copyright pages at a later date should the Examiner desire a copy.
89	Samadani <i>et al.</i> , "Identification of a Transthyretin Enhancer Site That Selectively Binds the Hepatocyte Nuclear Factor-3 β Isoform," <i>Gene Expression</i> 6:23-33 (1996);
90	Sambrook <i>et al.</i> , <i>Molecular Cloning, a Laboratory Manual</i> , Cold Spring Harbor Laboratories, New York (1989) (Title and Copyright Pages Only);

Examiner:

Baird A. Hines

Date Considered:

1/19/02

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN 003C1

Serial No. Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

B2	91	Samulski <i>et al.</i> , "Helper-Free Stocks Of Recombinant Adeno-Associated Viruses: Normal Intergration Does Not Require Viral Gene Expression", <i>J. Virol.</i> , 63:3822-3828 (1989);
	92	Sanberg <i>et al.</i> , XXth Int. Congress of the World Fed. of Hemophilia (1992); Reference could not be obtained at this time. Will provide a copy at a later date should the Examiner desire a copy.
	93	Schlehofer <i>et al.</i> , "Vaccinia Virus, Herpes Simplex Virus, and Carcinogens Induce DNA Amplification in a Human Cell Line and Support Replication of a Herpesvirus Dependent Parvovirus," <i>Virol.</i> , 152:110-117 (1986);
	94	Shelling and Smith, "Targeted Integration Of Transfected And Infected Adeno-Associated Virus Vectors Containing The Neomycin Resistance Gene", <i>Gene Ther.</i> , 1:165-169 (1994);
	95	Shigekawa <i>et al.</i> , "Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells," <i>BioTechn.</i> , 6:742-751 (1988);
	96	Snyder, <i>Current Protocols in Genetics</i> , Chapter 12, John Wiley and Sons (1997); Reference could not be obtained at this time. Will provide a copy at a later date should the Examiner desire a copy.
	97	Thomson <i>et al.</i> , "Human Herpesvirus 6 (HHV-6) Is a Helper Virus for Adeno-Associated Virus Type 2 (AAV-2) and the AAV-2 <i>rep</i> Gene Homologue in HHV-6 Can Mediate AAV-2 DNA Replication and Regulate Gene Expression," <i>Virol.</i> , 204:304-311 (1994);
	98	Toole <i>et al.</i> , "Molecular cloning of a cDNA encoding human antihemophilic factor," <i>Nature</i> 312:342-347 (1984);
	99	Uetsuki <i>et al.</i> , "Isolation and Characterization of the Human Chromosomal Gene for Polypeptide Chain Elongation Factor-1 α ," <i>J. Biol. Chem.</i> , 264:5791 (1989);
	100	Vehar <i>et al.</i> , "Structure of human factor VIII," <i>Nature</i> 312:337-342 (1984);
	101	Vincent <i>et al.</i> , "Replication and Packaging Of HIV Envelope Genes In A Novel Adeno-Associated Virus Vector System," in <i>Vaccines 90</i> , pp. 353-359, Cold Spring Harbor Laboratory Press (1990);
	102	Voss <i>et al.</i> , "The role of enhancers in the regulation of cell-type-specific transcriptional control," <i>Trends Biochem. Sci.</i> , 11:287-289 (1986);
	103	Wood <i>et al.</i> , "Expression of active human factor VIII from recombinant DNA clones," <i>Nature</i> 312:330-337 (1984);
	104	Yan <i>et al.</i> , "Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice," <i>EMBO J.</i> 9:869-878 (1990);
	105	Yonemura <i>et al.</i> , "Efficient production of recombinant human factor VIII by the expression of their heavy and light chains," <i>Prot. Engineer.</i> , 6:669-674 (1993);
	106	Young <i>et al.</i> , "Adeno-Associated Virus - an Extreme State of Viral Defectiveness," <i>Prog. Med. Virol.</i> , 25:113-132 (1979);
	107	Zhou <i>et al.</i> , "Adeno-Associated Virus 2-Mediated High Efficiency Gene Transfer Into Immature And Mature Subsets Of Hematopoietic Progenitor Cells In Human Umbilical Cord Blood", <i>J. Exp. Med.</i> , 179:1867-1875 (1994).
	108	Conrad <i>et al.</i> , "Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung," <i>Gene Ther.</i> , 3: 658-668 (1996)
	109	Byrnes <i>et al.</i> , "Immunological Instability of Persistent Adenovirus Vectors in the Brain: Peripheral Exposure to Vector Leads to Renewed Inflammation, Reduced Gene Expression, and Demyelination," <i>J. Neuroscience</i> 16: 3045-3055 (1996)
	110	Yang <i>et al.</i> , "Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes <i>in vivo</i> ," <i>Gene Ther.</i> , 3: 137-144 (1996)
	111	Yang <i>et al.</i> , "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy," <i>Proc. Natl. Acad. Sci. USA</i> 91: 4407-4411 (1994)
	112	Kass-Eisler <i>et al.</i> , "The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer," <i>Gene Ther.</i> , 1: 395-402 (1994)
	113	Mizuno <i>et al.</i> , "Adeno-associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjunction with Ganciclovir Administration," <i>Jpn. J. Cancer Res.</i> , 89: 76-80 (1998)
	114	Verma and Somia, "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242 (1997)
	115	Kaplitt <i>et al.</i> , "Viral Vectors for Gene Delivery and Expression in the CNS," in <i>Methods: A Companion to Methods in Enzymology</i> 10: 343-350 (1996)
PV	116	Anderson, "Human gene therapy," <i>Nature</i> 392:25-30 (1998)

Examiner: B. M. A. H.

Date Considered: 1/9/92

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN-00301

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

DL	117	Jooss <i>et al.</i> , "Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers," <i>J. Virol.</i> , 72:4212-4223 (1998)
	118	Rodriguez <i>et al.</i> , "DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination," <i>J. Virol.</i> , 72:5174-5181 (1998)
	119	Szomolanyi-Tsuda <i>et al.</i> , "T-Cell-Independent Immunoglobulin G Responses In Vivo Are Elicited by Live-Virus Infection but Not by Immunization with Viral Proteins or Virus-Like Particles," <i>J. Virol.</i> , 72:6665-6670 (1998)
	120	Ulmer <i>et al.</i> , "Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA," <i>J. Virol.</i> , 72:5648-5653 (1998)
	121	Tsuji <i>et al.</i> , "Recombinant Sindbis Viruses Expressing a Cytotoxic T-Lymphocyte Epitope of a Malaria Parasite or of Influenza Virus Elicit Protection against the Corresponding Pathogen in Mice," <i>J. Virol.</i> , 72:6907-6910 (1998)
	122	Yauch <i>et al.</i> , "Role of Individual T-Cell Epitopes of Theiler's Virus in the Pathogenesis of Demyelination Correlates with the Ability to Induce a Th1 Response," <i>J. Virol.</i> , 72:6169-6174 (1998)
DL	123	Xiao <i>et al.</i> , "Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Aden-Associated Virus Vector," <i>J. Virol.</i> , 70:8098-8108 (1996)

Examiner:

Brian G. Hone

Date Considered:

1/2/02

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN, 003C1

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
BZ	1	4,965,199	10/23/90	Capon <i>et al.</i>			08/07/87
	2	5,843,742	12/01/98	Natsoulis <i>et al.</i>			09/08/95
	3	5,872,005	02/16/99	Wang <i>et al.</i>			05/12/95
	4	5,219,740	06/15/93	Miller <i>et al.</i>			02/13/87
DL	5	5,399,346	03/21/95	Anderson <i>et al.</i>			03/30/94
	6	5,255,347	06/06/93	Goldberg <i>et al.</i>			03/19/90
BZ	7	4,722,848	02/02/88	Paoletti <i>et al.</i>			06/19/84
	8	5,436,146	07/25/95	Shenk <i>et al.</i>			06/21/93
	9	5,474,935	12/12/95	Chatterjee <i>et al.</i>			11/03/93
	10	5,587,308	12/24/96	Carter <i>et al.</i>			06/02/92
	11	5,658,785	08/19/97	Johnson			06/06/94
	12	5,861,314	01/19/99	Philip <i>et al.</i>			06/06/95
	13	5,693,531	12/02/97	Chiorini <i>et al.</i>			11/24/93
	14	5,677,158	10/14/97	Zhou <i>et al.</i>			06/07/95
	15	5,252,479	10/12/93	Srivastava			11/08/91
	16	5,580,703	12/03/96	Kotin <i>et al.</i>			09/20/94
	17	5,658,776	08/19/97	Flotte <i>et al.</i>			06/07/95
DL	18	5,622,856	04/22/97	Natsoulis			08/03/95

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
BZ	19	WO 88/09809	12/15/88	PCT WIPO				
	20	WO 89/03429	04/20/89	PCT				
	21	WO 92/03545	03/05/92	PCT WIPO				
	22	0 592 836	04/20/94	EP				
	23	WO 96/15777	05/30/96	PCT WIPO				
	24	WO 96/13698	05/09/96	PCT				
	25	WO 93/24641	12/09/93	PCT				
	26	WO 95/07995	03/23/95	PCT				
BZ	27	WO 94/13788	06/23/94	PCT WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

BZ	28	Surosky <i>et al.</i> , "Adeno-Associated Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome," <i>J. Virol.</i> 71: 7951-7959 (1997)
	29	Miller and Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression," <i>BioTechn.</i> 7: 980-990 (1989)
BZ	30	Miller, "Retrovirus Packaging Cells," <i>Human Gene Ther.</i> 1: 5-14 (1990)

Examiner: B. J. d. H.

Date Considered: 1/9/02

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN.003C1

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Linda B. Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

DM	31	Scarpa <i>et al.</i> , "Characterization of Recombinant Helper Retroviruses from Moloney-Based Vectors in Ecotropic and Amphotropic Packaging Cell Lines," <i>Virol.</i> 180: 849-852 (1991)
	32	Burns <i>et al.</i> , "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells," <i>Proc. Natl. Acad. Sci. USA</i> 90: 8033-8037 (1993)
	33	Boris-Lawrie and Temin, "Recent advances in retrovirus vector technology," <i>Curr. Opin. Gen. Dev.</i> 3: 102-109 (1993)
	34	Haj-Ahmad and Graham, "Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene," <i>J. Virol.</i> 57: 267-274 (1986)
	35	Bett <i>et al.</i> , "Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors," <i>J. Virol.</i> 67: 5911-5921 (1993)
	36	Mittereder <i>et al.</i> , "Evaluation of the Efficacy and Safety of <i>In Vitro</i> , Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA," <i>Human Gene Ther.</i> 5: 717-729 (1994)
	37	Seth <i>et al.</i> , "Mechanism of Enhancement of DNA Expression Consequent to Cointernalization of a Replication-Deficient Adenovirus and Unmodified Plasmid DNA," <i>J. Virol.</i> 68: 933-940 (1994)
	38	Barr <i>et al.</i> , "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," <i>Gene Ther.</i> 1: 51-58 (1994)
	39	Berkner <i>et al.</i> , "Development of Adenovirus Vectors for the Expression of Heterologous Genes," <i>BioTechn.</i> 6: 616-629 (1988)
	40	Rich <i>et al.</i> , "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis," <i>Human Gene Ther.</i> 4: 461-476 (1993)
	41	Berns and Bochenky, "Adeno-associated Viruses: An Update," <i>Adv. Virus Res.</i> 32: 243-307 (1987)
	42	Mackett <i>et al.</i> , "The Construction and Characterization of Vaccinia Virus Recombinants Expressing Foreign Genes," in <i>DNA Cloning: A Practical Approach vol. II</i> , Glover <i>et al.</i> (ed.), pp. 191-211, Oxford; New York: IRL Press (1995)
	43	Han <i>et al.</i> , "Inhibition of Moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences," <i>Proc. Natl. Acad. Sci. USA</i> 88: 4313-4317 (1991)
	44	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90: 543-584 (1990)
	45	Hélène and Toulmé, "Specific regulation of gene expression by antisense, sense and antigene nucleic acids," <i>Biochim. Biophys. Acta</i> 1049: 99-125 (1990)
	46	Agrawal <i>et al.</i> , "Oligodeoxynucleoside phosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Acad. Natl. Sci. USA</i> 85: 7079-7083 (1988)
	47	Heikkilä <i>et al.</i> , "A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G ₀ to G ₁ ," <i>Nature</i> 328: 445-449 (1990)
	48	Samulski <i>et al.</i> , "Targeted integration of adeno-associated virus (AAV) into human chromosome 19," <i>EMBO J.</i> 10: 3941-3950 (1991)
	49	Kotin <i>et al.</i> , "Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination," <i>EMBO J.</i> 11: 5071-5078 (1992)
	50	Weitzman <i>et al.</i> , "Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA," <i>Proc. Natl. Acad. Sci. USA</i> 91: 5808-5812 (1994)
	51	Walz and Schlefor, "Modification of Some Biological Properties of HeLa Cells Containing Adeno-Associated Virus DNA Integrated Into Chromosome 17," <i>J. Virol.</i> 66: 2990-3002 (1992)
	52	Hu and Davidson, "The Inducible lac Operator-Repressor System is Functional in Mammalian Cells" <i>Cell</i> 48: 555-566 (1987)
	53	Urlaub <i>et al.</i> , "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity," <i>Proc. Natl. Acad. Sci. USA</i> 77: 4216-4220 (1980)
	54	Ringold <i>et al.</i> , "Co-Expression and Amplification of Dihydrofolate Reductase cDNA and the <i>Escherichia coli</i> XGPRT Gene in Chinese Hamster Ovary Cells," <i>J. Mol. Appl. Gen.</i> 1: 165-175 (1981)
RV	55	McVey <i>et al.</i> , "Properties of the DNA-Binding Domain of the Simian Virus 40 Large T Antigen," <i>Mol. Cell. Biol.</i> 9: 5525-5536 (1989)

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: AVIGEN. 00301

Serial No.: Unknown

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Couto *et al.*

Filing Date: Herewith

Group Art Unit: Unknown

(37 CFR § 1.98(b))

DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Bv	1	Connelly <i>et al.</i> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 88(10):3846-3853 (1996)
	2	Connelly <i>et al.</i> , "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 91(9):3273-3281 (May 1, 1998)
	3	Lozier <i>et al.</i> , "Gene Therapy and the Hemophilias," <i>JAMA</i> 271(1):47-51 (1994)
	4	Snyder <i>et al.</i> , "Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene Transfer of Recombinant AAV Vectors," <i>Nature Genetics</i> 16:270-276 (July 1997)
Bv	5	Zatloukal <i>et al.</i> , "In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> 91:5148-5152 (1994)

Examiner: B. M. & H. K.

Date Considered: 11/9/02

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.